

Special Issue

SARS-CoV-2 Serological Studies around the World

Message from the Guest Editors

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for COVID-19, a severe pneumonia leading to respiratory distress, has now spread around the world with more than 615 million people being infected. During the course of the pandemic, several variants carrying amino acid changes in the entire genome of SARS-CoV-2 emerged worldwide. The emergence of these variants was often accompanied by a loss of effectiveness of immune efficiency, induced by primary infection, vaccination or therapeutic treatments. The need for serological investigation to analyze the antibody responses, titer and duration elicited by primary infection or vaccination against the circulating variants will greatly help the identification of the populations at risk of re-infection and will help monitor the efficacy of COVID-19 vaccines, thus, accelerating the public health policy decision. For this Special Issue, both reviews and research articles describing the SARS-CoV-2 sero-epidemiology using robust system or gold standard tools will be welcome.

Guest Editors

Dr. Julien Mélade

Dr. Paola Mariela Saba Villarroel

Dr. François Meurens

Deadline for manuscript submissions

closed (20 October 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/145198

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).